Effects of prophylactic ramosetron and ondansetron on corrected QT interval during general anesthesia
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Sang-Hyun | - |
dc.contributor.author | Lee, Su-Myung | - |
dc.contributor.author | Kim, Young-Kwon | - |
dc.contributor.author | Park, Sun-Young | - |
dc.contributor.author | Lee, Joon-Ho | - |
dc.contributor.author | Cho, Sung-Hwan | - |
dc.contributor.author | Chai, Won-Seok | - |
dc.contributor.author | Jin, Hee-Cheol | - |
dc.date.accessioned | 2021-08-11T22:24:05Z | - |
dc.date.available | 2021-08-11T22:24:05Z | - |
dc.date.issued | 2014-11 | - |
dc.identifier.issn | 0952-8180 | - |
dc.identifier.issn | 1873-4529 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/11726 | - |
dc.description.abstract | Study Objective: To evaluate whether ramosetron increases the corrected QT (QTc) interval. Design: Prospective, randomized, controlled study. Setting: Operating room. Patients: 135 patients undergoing elective laparoscopic cholecystectomy. Intervention: Patients were allocated to three groups to receive ondansetron 4 mg (Group O4), ramosetron 0.3 mg (Group R), or ondansetron 8 mg (Group O8). The study drugs were administered intravenously approximately 15 minutes before the end of surgery. Measurement: The QT interval for 10 minutes after administration was recorded. The QTc interval was calculated according to the Fridericia (QTcF) formula. The primary outcome was the QTcF interval among the three groups during the 10 minutes after administration of the study drugs. Main Results: The QTcF interval was not significantly prolonged after administration of ondansetron 4 mg and ramosetron. It was significantly increased from one minute after administration until 7 minutes after ondansetron 8 mg (Group O8). The QTcF interval was significantly longer in Group O8 at 1, 2, 3, 4, and 5 minutes. Conclusions: The prophylactic administration 0.3 mg of ramosetron does not increase the QTc interval. Ondansetron 8 mg increases the QTc interval more so than 4 mg of ondansetron. (C) 2014 Elsevier Inc. All rights reserved. | - |
dc.format.extent | 6 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Elsevier BV | - |
dc.title | Effects of prophylactic ramosetron and ondansetron on corrected QT interval during general anesthesia | - |
dc.type | Article | - |
dc.publisher.location | 미국 | - |
dc.identifier.doi | 10.1016/j.jclinane.2014.02.011 | - |
dc.identifier.scopusid | 2-s2.0-84922449114 | - |
dc.identifier.wosid | 000346222400001 | - |
dc.identifier.bibliographicCitation | Journal of Clinical Anesthesia, v.26, no.7, pp 511 - 516 | - |
dc.citation.title | Journal of Clinical Anesthesia | - |
dc.citation.volume | 26 | - |
dc.citation.number | 7 | - |
dc.citation.startPage | 511 | - |
dc.citation.endPage | 516 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Anesthesiology | - |
dc.relation.journalWebOfScienceCategory | Anesthesiology | - |
dc.subject.keywordPlus | POSTOPERATIVE NAUSEA | - |
dc.subject.keywordPlus | PROLONGATION | - |
dc.subject.keywordPlus | DROPERIDOL | - |
dc.subject.keywordPlus | PREVENTION | - |
dc.subject.keywordPlus | HUMANS | - |
dc.subject.keywordAuthor | Laparoscopic cholecystectomy | - |
dc.subject.keywordAuthor | Ondansetron | - |
dc.subject.keywordAuthor | Postoperative nausea and vomiting | - |
dc.subject.keywordAuthor | QT interval | - |
dc.subject.keywordAuthor | QTc interval | - |
dc.subject.keywordAuthor | Ramosetron | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.